-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai, November 1, 2021/PRNewswire/ - Today, Shanghai Ailisi Pharmaceutical Technology Co.
Lung cancer is the malignant tumor with the highest incidence and fatality rate in China
EGFR-TKI targeted therapy drugs have become the standard first-line treatment for advanced non-small cell lung cancer with EGFR-sensitive mutations.
However, there are still unmet needs for the treatment of EGFR-sensitive mutant NSCLC, and there is still room for improvement in the therapeutic efficacy of patients with lung cancer and brain metastases.
The main investigator of the FURLONG study, Professor Yuankai Shi from the National Cancer Center/Tumor Hospital of the Chinese Academy of Medical Sciences, pointed out that there are still unmet needs for the first-line treatment of NSCLC patients with EGFR gene-sensitive mutations; as the specific data of the FURLONG study is released in the future, it will be verified again.
Vometinib is the third-generation EGFR-TKI drug for the treatment of advanced lung cancer, and it is a national Class 1 new drug originally developed in China
"The clinical research results of vometinib and its performance in clinical practice have always brought us surprises.
About FURLONG Research
The FURLONG study is a randomized, double-blind, positive-controlled, multi-center phase III clinical study that aims to compare vometinib mesylate (AST2818) and gefitinib in the first-line treatment of locally advanced or metastatic EGFR sensitive mutations The effectiveness and safety of patients with non-small cell lung cancer
About Ivesa® (Vormetinib Mesylate)
Ivesa® is approved in the country for the treatment of disease progression during or after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and the presence of EGFR T790M mutation-positive areas is confirmed by testing Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) have the characteristics of "dual activity, high selection, strong tumor shrinkage, and good safety"
About Iris
Shanghai Ailisi Pharmaceutical Technology Co.
On December 2, 2020, Shanghai Ailisi Pharmaceutical Technology Co.
Source: Ellis
